US FDA Says Opioid Database Firm With Purdue Pharma Connections Reported No Conflicts
Executive Summary
Amid criticism of its contract to evaluate opioid data from the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) survey programs, the FDA says federal databases lack the necessary information on opioid misuse.